ArticleHemaSphere2025

Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia.

Christine E Ryan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.